RSS Feed
June 3rd, 2012 
FAKE NEWS for the Zionist agenda 
Susanne Posel
Occupy Corporatism
June 3, 2012
Research scientists at the International Agency for Research on Cancer (IARC), which is a UN off-shoot agency of the World Health Organization (WHO) and the American Cancer Society (ACS) have come together to conduct a study that projects cancer rates to rise by 75% by the year 2030.
Freddie Bay, head of the study by the IARC describes cancer as a “by-product” of under developed countries.
Bay suggests there could be 22.2 million undiscovered cancer cases in 184 nations by 2030. Bay makes this prediction from cancer trends and demographic projections from data provided by the UN.
This number is up from the 127 million cases reported in 2008.
By blaming population growth, the study claims that 1-5th of the new cancer cases will come from preventable causes; dependent on access to proper medical care.
In developing countries, Bay cites that infection-based cancers are most prevalent. Lifestyle is to blame for the recent spike in breast, lung and colon cancer.
While some cancers are linked to infection (i.e. cervical, liver and stomach cancers), others are surging to the forefront because of diet, lack of exercise, smoking and drinking. Those social habits are raising the incidents of lung, colon and breast cancers, according to researchers.
The study predicts that by 2030 more than 90% of the poorer countries will be afflicted by cancer.
While health initiatives now deal with saving under developed nations from malaria, AIDS/HIV and polio; those same organizations would do well to turn their attention to developing cancer vaccines and medications to be distributed en masse, suggests the study.
Bray also remarks that the cost of bringing health care to under developed nations is great, while cancer rates are expected to rise regardless of the preventative measures. Bray admonishes that costly cancer treatments to assist nations like Africa need to focus on prevention. This cancer trend would subside, Bray says, if cancer vaccines were distributed.
John Groopman, of the Johns Hopkins Bloomberg School of Public Health in Baltimore, advises health officials to “act now” to circumvent future cancer cases. ‘‘There’s no need for the lung cancer burden in the West to be transferred to developing countries. It’s a misconception that nothing can be done. If we employed cervical cancer screening and the vaccine (to prevent it), we could eliminate cervical cancer in this century.”
Luckily, Bristol-Myers Squibb (BMS) have two experimental drugs that are purported to boost the human immune system against developing cancer.
BMS claims the drugs will combat several types of cancer.
These drugs, researchers say, “empower the immune system to recognize cancer cells as an enemy and attack them.”
“The immune system isn’t like any drug out there,” Dr. Topalian said. “It has memory, similar to when we were vaccinated against infectious diseases. You retain that memory pretty much for life. The same should hold true for cancer immunotherapy.”
By focusing on the immune system, researchers and pharmaceutical corporations (like Roche Holding SA Genetech, Merick Co, GlaxoSmithKline PLC) are pursuing “immunotherapies”.
Five hundred patients in advanced stages of cancer were participants in the study. The drugs tested displayed a more than 20% increase in long-term survival of those studied. This finding encouraged researchers working with immunotherapy to see it as a viable strategy against cancer.
These immunotherapies will be designed to be used in combination with traditional drugs and therapies already on the market.
BMS is confident that their drug will receive approval and therefore are advancing their trials to rush their immunotherapy to market as soon as possible.
Thanks to the US Senate’s recent approval of the Food and Drug Administration (FDA), in conjunction with certain pharmaceutical corporations, for a $6.4 billion “agreement fee” in the new Food and Drug Administration Safety and Innovation Act, S. 3187 (FDASI), this new cancer therapy will most likely be expedited to the consumer market.
The focus of this collaboration will identify new uses for drugs that have already been approved by FDA.
Drug manufacturers and medical device makers are anxious to work with the US government. This will mean their treatments will be reviewed and approved faster than they currently are. The FDASI specifies that certain measures be taken to expedite the approval of medical treatments under the guise of “life-threatening” or rush monitoring devices to mitigate drug shortages.
The FDASI is part of Obama’s program to use the US government and drug makers together to discover new ways to use old drugs; as well as find new pharmaceutical answers to new diseases.
Called the Codex Alimentarious, this intiative focuses the US government and pharmaceutical corporations into a relationship to drug the American population.
Codex Alimentarious (CA) is a creation of WHO and the Food and Agriculture Organization of the United Nations. The CA seeks to enforce international standards and codes on nations in a securitization of the world’s food supply and healthcare.
By controlling the means of food production, transportation and distribution, the CA will ensure the standards set forth by the UN are the basis for all national legislation.
Posted in 
Tags: 
